Subscribe
ugisrigba
Ugis Rigba / Shutterstock.com
28 May 2020Big PharmaRory O'Neill

Report slams big pharma influence in EU-funded project

A  new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent